Apalutamide Patent Expiration
Apalutamide is Used for treating various forms of prostate cancer, including non-metastatic and metastatic types, in combination with different therapies. It was first introduced by Janssen Biotech Inc
Apalutamide Patents
Given below is the list of patents protecting Apalutamide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Erleada | US11963952 | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | Jan 30, 2040 | Janssen Biotech |
| Erleada | US10702508 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer | Apr 30, 2038 | Janssen Biotech |
| Erleada | US10052314 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | Sep 23, 2033 | Janssen Biotech |
| Erleada | US10849888 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | Sep 23, 2033 | Janssen Biotech |
| Erleada | US9884054 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | Sep 23, 2033 | Janssen Biotech |
| Erleada | USRE49353 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | Sep 23, 2033 | Janssen Biotech |
| Erleada | US9481663 | Crystalline forms of an androgen receptor modulator | Jun 04, 2033 | Janssen Biotech |
| Erleada | US8445507 | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases | Sep 15, 2030 | Janssen Biotech |
| Erleada | US8802689 | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases | Mar 27, 2027 | Janssen Biotech |
| Erleada | US9388159 | Substituted diazaspiroalkanes as androgen receptor modulators | Mar 27, 2027 | Janssen Biotech |
| Erleada | US9987261 | Substituted diazaspiroalkanes as androgen receptor modulators | Mar 27, 2027 | Janssen Biotech |
Apalutamide's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List